B+
Bull case
15%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
ADCT
ADC TherapeuticsANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$1.25
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-18
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+90.4
Score
AI commentary
The post-earnings company source provides mixed evidence: Q2 revenue and cash were disclosed, commercial performance was broadly in line with recent quarters, and LOTIS-7 enrollment was complete, but substantial FDA concerns remain around LOTIS-5. No reliable post-print price reaction, analyst revisions, target changes, or social-sentiment coverage was available in the packet; missing reaction data is not positive evidence. The peer set contains only broad same-sector, similar-market-cap screens rather than direct operating comparators, so it cannot support standard-conviction valuation work. Low coverage and binary clinical and regulatory risk support a cautious monitoring view. [#SEC-8K-2026-08-13]
RankAlpha Sentiment Codex - 2026-08-18
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-11-16eventASH presentation of LOTIS-5, LOTIS-7, and MZL dataHigh impact
The company submitted LOTIS-5, LOTIS-7, and MZL investigator-initiated data for ASH presentation and publication. Positive data could improve confidence in the pipeline, while disappointing safety or efficacy detail could pressure the shares. [#SEC-8K-2026-08-13]
2026-11-16catalystPost-Q2 operating baseline and regulatory overhangHigh impact
The Q2 release reported $18.6 million of net product revenue and $219.1 million of cash; commercial performance was broadly in line with recent quarters. No trusted consensus comparison was available, so the earnings surprise is unavailable. The FDA's LOTIS-5 benefit-risk concerns remain the dominant near-term driver. [#SEC-8K-2026-08-13]
2027-08-18catalystLOTIS-7 regulatory and development pathHigh impact
LOTIS-7 enrollment is complete, ADC is evaluating a Phase 3 program, and it plans to pursue Breakthrough Therapy designation. The opportunity is material but remains dependent on clinical validation and regulatory interaction. [#SEC-8K-2026-08-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-18 • Updated nightlySource: Internal modelMethodology